Study to Evaluate the Long-term Antibody Persistence of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine (GSK134612) Versus Mencevax ACWY in Healthy Adolescents and Adults and Booster Response to MenACWY-TT Vaccine Administered at 10 Years Post-primary Vaccination

PHASE3CompletedINTERVENTIONAL

Enrollment

311

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

February 28, 2018

Study Completion Date

August 31, 2018

Conditions

Infections, Meningococcal

Interventions

BIOLOGICAL

Meningococcal vaccine GSK134612

1 dose administered intramuscularly in the non-dominant deltoid region.

Trial Locations (2)

Philippine General Hospital, Manila

Research Institute for Tropical Medicine, Muntinlupa City